This systematic review and meta-analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.<h4>Methods</h4>Literature searches of five databases were performed. The gene discussed is ERBB2; the disease is prostate cancer.